Nothing Special   »   [go: up one dir, main page]

BRPI0518869A2 - agentes citotàxicos compreendendo taxanos - Google Patents

agentes citotàxicos compreendendo taxanos

Info

Publication number
BRPI0518869A2
BRPI0518869A2 BRPI0518869-5A BRPI0518869A BRPI0518869A2 BR PI0518869 A2 BRPI0518869 A2 BR PI0518869A2 BR PI0518869 A BRPI0518869 A BR PI0518869A BR PI0518869 A2 BRPI0518869 A2 BR PI0518869A2
Authority
BR
Brazil
Prior art keywords
cytotoxic agents
taxanes
therapeutic use
relates
novel cytotoxic
Prior art date
Application number
BRPI0518869-5A
Other languages
English (en)
Inventor
Michael L Miller
Ravi V J Chari
Erkan Baloglu
Alain Commercon
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34931583&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0518869(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of BRPI0518869A2 publication Critical patent/BRPI0518869A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

AGENTES CITOTàXICOS COMPREENDENDO TAXANOS. A presente invenção refere-se a novos agentes citotóxicos e seu uso terapêutico. Mais especificamente, a invenção refere-se a novos agentes citotóxicos compreendendo taxanos e seu uso terapêutico. Estes novos agentes citotóxicos têm uso terapêutico como um resultado de liberaçpara uma específica população de células em uma maneira alvejada através de ligação química de taxano a um agente de ligação de célula.
BRPI0518869-5A 2004-12-07 2005-12-02 agentes citotàxicos compreendendo taxanos BRPI0518869A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04292898A EP1669358A1 (en) 2004-12-07 2004-12-07 Cytotoxic agents comprising new taxanes
PCT/EP2005/014177 WO2006061258A2 (en) 2004-12-07 2005-12-02 Cytotoxic agents comprising new taxanes

Publications (1)

Publication Number Publication Date
BRPI0518869A2 true BRPI0518869A2 (pt) 2008-12-16

Family

ID=34931583

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518869-5A BRPI0518869A2 (pt) 2004-12-07 2005-12-02 agentes citotàxicos compreendendo taxanos

Country Status (22)

Country Link
US (1) US7667054B2 (pt)
EP (2) EP1669358A1 (pt)
JP (1) JP2008523019A (pt)
KR (1) KR20070085781A (pt)
CN (1) CN101094857A (pt)
AR (1) AR054100A1 (pt)
AU (1) AU2005313444B2 (pt)
BR (1) BRPI0518869A2 (pt)
CA (1) CA2588587A1 (pt)
DO (1) DOP2005000248A (pt)
EA (1) EA012625B1 (pt)
IL (1) IL183404A0 (pt)
MA (1) MA29103B1 (pt)
MX (1) MX2007006765A (pt)
MY (1) MY144632A (pt)
NO (1) NO20073033L (pt)
NZ (1) NZ555406A (pt)
PE (2) PE20061060A1 (pt)
TW (1) TW200637836A (pt)
UY (1) UY29249A1 (pt)
WO (1) WO2006061258A2 (pt)
ZA (1) ZA200704790B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
EP2335728A1 (en) 2001-05-11 2011-06-22 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
MX338185B (es) * 2007-01-25 2016-04-05 Dana Farber Cancer Inst Inc Uso de anticuerpos anti-egfr en el tratamiento de enfermedad mediada por egfr mutante.
US20080207743A1 (en) * 2007-02-28 2008-08-28 Rodger Lamb Biologically Active Taxane Analogs and Methods of Treatment
WO2008115404A1 (en) * 2007-03-15 2008-09-25 Ludwing Institute For Cancer Research Treatment method using egfr antibodies and src inhibitors and related formulations
CN101896503B (zh) 2007-08-14 2018-05-22 路德维格癌症研究所有限公司 靶向egf受体的单克隆抗体175及其衍生物和用途
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
FR2949469A1 (fr) 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
US20110076232A1 (en) * 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
TW201117814A (en) 2009-10-02 2011-06-01 Sanofi Aventis New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody
CN101851231A (zh) * 2010-05-27 2010-10-06 东北林业大学 一种多西紫杉醇新衍生物的合成方法及其在制备抗肿瘤药物中的应用
FR2963007B1 (fr) 2010-07-26 2013-04-05 Sanofi Aventis Derives anticancereux, leur preparation et leur application therapeutique
LT3210627T (lt) 2012-07-12 2023-04-11 Hangzhou Dac Biotech Co., Ltd Ląsteles surišančiųjų molekulių konjugatai su citotoksinėmis medžiagomis
WO2014080251A1 (en) 2012-11-24 2014-05-30 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
WO2015127685A1 (en) 2014-02-28 2015-09-03 Hangzhou Dac Biotech Co., Ltd Charged linkers and their uses for conjugation
CN104693156A (zh) * 2014-10-22 2015-06-10 上海大学 9,10-二羟基-1-去氧紫杉醇类似物及其制备方法
WO2015151081A2 (en) 2015-07-12 2015-10-08 Suzhou M-Conj Biotech Co., Ltd Bridge linkers for conjugation of a cell-binding molecule
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
KR20220147720A (ko) 2016-11-14 2022-11-03 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703247A (en) * 1993-03-11 1997-12-30 Virginia Tech Intellectual Properties, Inc. 2-Debenzoyl-2-acyl taxol derivatives and methods for making same
FR2742751B1 (fr) * 1995-12-22 1998-01-30 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
CA2388063C (en) * 1999-11-24 2010-06-08 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
US6596757B1 (en) * 2002-05-14 2003-07-22 Immunogen Inc. Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
WO2004013093A2 (en) * 2002-08-02 2004-02-12 Immunogen, Inc. Cytotoxic agents containing novel potent taxanes and their therapeutic use

Also Published As

Publication number Publication date
MA29103B1 (fr) 2007-12-03
NO20073033L (no) 2007-08-28
EA200701251A1 (ru) 2007-12-28
JP2008523019A (ja) 2008-07-03
AU2005313444B2 (en) 2011-11-10
DOP2005000248A (es) 2007-02-15
MY144632A (en) 2011-10-14
US7667054B2 (en) 2010-02-23
AU2005313444A1 (en) 2006-06-15
PE20061060A1 (es) 2006-11-14
IL183404A0 (en) 2007-10-31
WO2006061258A3 (en) 2006-09-28
TW200637836A (en) 2006-11-01
MX2007006765A (es) 2007-08-16
ZA200704790B (en) 2008-08-27
US20060178427A1 (en) 2006-08-10
CA2588587A1 (en) 2006-06-15
CN101094857A (zh) 2007-12-26
KR20070085781A (ko) 2007-08-27
PE20110001A1 (es) 2011-01-21
WO2006061258A2 (en) 2006-06-15
EP1824858A2 (en) 2007-08-29
AR054100A1 (es) 2007-06-06
UY29249A1 (es) 2006-06-30
NZ555406A (en) 2011-02-25
EA012625B1 (ru) 2009-10-30
EP1669358A1 (en) 2006-06-14

Similar Documents

Publication Publication Date Title
BRPI0518869A2 (pt) agentes citotàxicos compreendendo taxanos
UY29086A1 (es) Nuevas composiciones farmacéuticas para el tratamiento de trastornos hiperproliferativos.
CR11723A (es) Agente para tratar enfermedad
DOP2006000179A (es) 7-aza-indazoles sustituidos, composiciones que les contienen, procedimiento de fabricación y utilización
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
NI201100082A (es) Compuestos de isoindolina para uso en el tratamiento de cáncer.
CL2013001138A1 (es) Composicion que comprende anticuerpo biespecífico cd19xcd3 para tratar masa tumoral de tejido de ganglios linfáticos y/o linfoma extranodal causado por el linfoma b difuso de células grandes (lbdcg); kit farmacéutico; uso de la composición.
NO20080068L (no) Topisk unguale formuleringer
CO6351786A2 (es) Inkibidores de la cinasa map p38
AR047928A1 (es) Derivados de tetrahidropiridoindol
CL2009000035A1 (es) Compuestos derivados 3-espiro-heterociclo-1il-5h-ciclopentan[d]pirimidin-indol, util para inhibir la actividad de akt quinasa; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades tal como cancer, fibrosis quistica, diabetes, enfermedad de alzheimer, entre otras.
ECSP099426A (es) Compuestos de 4-hidroxi-2-oxo-2,3-dihidro-1,3-benzotiazol-7il para la modulación de la actividad del adrenoreceptor beta2
CL2011000144A1 (es) Compuestos derivados de benzo (1,4) dioxin-2-ilmetil-sulfamida; composiciones farmaceuticas que los contienen; proceso para prepararlos y uso en el tratamiento de la ansiedad, epilepsia, dolor, abuso de sustancias, trastornos relacionados, entre otros.
BRPI0915439B8 (pt) composição de gel tópica, bem como uso de um agente ativo para tratamento de ceratose actínica em combinação com um agente ceratoliticamente ativo para preparação da referida composição
ECSP088252A (es) 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricación y utilización
EA201001288A1 (ru) Лечение гипертонии 25-гидроксивитамином d3
CL2011002160A1 (es) Compuestos derivados de 3-amino-2-mercaptoquinolinas sustituidas; composicion farmaceutica que contiene dichos compuestos; y su uso para tratar dolor, epilepsis, incontinencia urinaria, manias, migraña, trastornos bipolares, enfermedades cognitivas, discinesia asociada a la distonia y/o incontinencia urinaria.
CR20110226A (es) Composición para tratar enfermedad
UY29250A1 (es) Agentes citotóxicos que comprenden nuevos taxanos modificados en c-2.-
ES2723778T3 (es) Terapia dirigida a células madre cancerosas y contra cáncer resistente a fármacos
CL2011000614A1 (es) Forma de dosificacion oral solida que comprende alisquireno solo o en combinacion con otro agente activo; proceso de preparacion; y uso en el tratamiento de enfermedades tales comohipertension, angina, ateroesclerosis, entre otras.
DK1729732T3 (da) Anioniske hydrogelmatricer med pH-afhængig frigivelse som lægemiddelbærere
BR112012031471A2 (pt) mistura para tratamento de fertilizantes
ITMI20052515A1 (it) Formulazione farmaceutica per il trattamento della osteoartrite
PA8657901A1 (es) Composicion que comprende una epotilona y metodos para producir dicha composicion

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 7A. ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2202 DE 19/03/2013.